Aggrenox
NDC Package 68151-3971-6

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Aggrenox is a medication used to reduce the risk of stroke in patients who have had "mini-strokes" (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke. Marketed by Carilion Materials Management, this product is identified by NDC 68151-3971 and is authorized under FDA application NDA020884.

Identification & Billing

NDC Package Code
68151-3971-6
Package Description
1 CAPSULE, EXTENDED RELEASE in 1 PACKAGE
Product Code
68151-3971
11-Digit Billing Format
68151397106
RxNorm Crosswalk
  • RxCUI: 1362082 - Aggrenox 25 MG / 200 MG 12HR Extended Release Oral Capsule
  • RxCUI: 1362082 - 12 HR aspirin 25 MG / dipyridamole 200 MG Extended Release Oral Capsule [Aggrenox]
  • RxCUI: 1362082 - 12 HR ASA 25 MG / Dipyridamole 200 MG Extended Release Oral Capsule [Aggrenox]
  • RxCUI: 1362082 - Aggrenox 25/200 (aspirin 25 MG / dipyridamole 200 MG) 12HR Extended Release Oral Capsule
  • RxCUI: 1362082 - Aggrenox 25/200 12HR Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Aggrenox
Dosage Form
-
Usage Information
This medication is used to reduce the risk of stroke in patients who have had "mini-strokes" (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke. It contains two medications: a very low dose of aspirin (25 milligrams per tablet) and dipyridamole in a slow-release form. Low-dose aspirin and dipyridamole are antiplatelet drugs that work to keep blood flowing to the brain by stopping platelets from clumping together. This helps prevent the platelets from forming blood clots, which can lodge in the brain and cause a certain type of stroke (ischemic stroke).

Regulatory & Marketing

Labeler Name
Carilion Materials Management
FDA Application #
NDA020884
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-19-1999
Listing Expiration
12-31-2018
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68151-3971-6 identifies a specific commercial package of 1 capsule, extended release in 1 package of Aggrenox, labeled by Carilion Materials Management. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Carilion Materials Management on December 19, 1999. The current certification is valid through December 31, 2018.

What are the primary indications for this medication?

This medication is used to reduce the risk of stroke in patients who have had "mini-strokes" (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke. It contains two medications: a very low dose of aspirin (25 milligrams per tablet) and dipyridamole in a slow-release form. Low-dose aspirin and dipyridamole are antiplatelet drugs that work to keep blood flowing to the brain by stopping platelets from clumping together. This helps prevent the platelets from forming blood clots, which can lodge in the brain and cause a certain type of stroke (ischemic stroke).

How is this Carilion Materials Management product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68151397106. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68151-3971-6
11-Digit CMS (5-4-2)
68151-3971-06

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.